Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161738 | 0.93 | TP53 (0.42) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13182879 | 0.90 | TP53 (0.34) | TP53P2RY12CD274PDCD1BRD4 | |
| SCHEMBL12177359 | 0.90 | CD274 (0.39) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9922238 | 0.88 | TP53 (0.37) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9923270 | 0.87 | TP53 (0.39) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9922239 | 0.87 | TP53 (0.35) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9923266 | 0.85 | CNR1 (0.40) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9923268 | 0.83 | TP53 (0.36) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9923267 | 0.83 | CNR1 (0.38) | TP53LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9922419 | 0.83 | FBP1 (0.40) | TP53LMNAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | TP53 4462/4885LMNA 3576/4885MEN1 4498/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | TP53 3851/4885LMNA 3577/4885MEN1 4750/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | TP53 4435/4885LMNA 3603/4885MEN1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.